These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 24636286

  • 1. [Analysis of a randomized, double-blind, double-dummy, controlled, multicenter study confirmed the similar therapeutic efficacies of entecavir maleate and entecavir for treatment of HBeAg-positive chronic hepatitis B].
    Xu JH, Yu YY, Si CW, Zeng Z, Li J, Mao Q, Zhang DZ, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J, Xu ZN.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Dec; 21(12):881-5. PubMed ID: 24636286
    [Abstract] [Full Text] [Related]

  • 2. [A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of HBeAg-negative chronic hepatitis B: results at week 48].
    Xu JH, Yu YY, Si CW, Zeng Z, Zhang DZ.
    Zhonghua Gan Zang Bing Za Zhi; 2012 Jul; 20(7):512-6. PubMed ID: 23044236
    [Abstract] [Full Text] [Related]

  • 3. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH, Shi KQ, Dai ZJ, Ye C, Chen YP.
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [Abstract] [Full Text] [Related]

  • 4. 240-week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C.
    Xu JH, Fan YN, Yu YY, Si CW, Zeng Z, Xu ZN, Li J, Mao Q, Zhang DZ, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J.
    J Viral Hepat; 2022 Oct; 29(10):862-867. PubMed ID: 35737855
    [Abstract] [Full Text] [Related]

  • 5. [A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B].
    Yao GB, Zhu M, Wang YM, Xu DZ, Tan DM, Chen CW, Hou JL.
    Zhonghua Nei Ke Za Zhi; 2006 Nov; 45(11):891-5. PubMed ID: 17313873
    [Abstract] [Full Text] [Related]

  • 6. Entecavir maleate versus entecavir in Chinese chronic hepatitis B predominantly genotype B or C: Results at week 144.
    Xu JH, Wang S, Xu ZN, Yu YY, Si CW, Zeng Z, Li J, Mao Q, Zhang DZ, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J.
    J Viral Hepat; 2017 Oct; 24(10):877-884. PubMed ID: 28345157
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
    Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett-Smith H.
    Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
    Lu JJ, Liu K, Ma YJ, Wang J, Chen EQ, Tang H.
    J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
    Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, Lesmana L, Yuen MF, Jeffers L, Sherman M, Min A, Mencarini K, Diva U, Cross A, Wilber R, Lopez-Talavera J.
    Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670
    [Abstract] [Full Text] [Related]

  • 15. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N, Xu JH, Yu M, Wang S, Si CW, Yu YY.
    World J Gastroenterol; 2015 Nov 21; 21(43):12421-9. PubMed ID: 26604649
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH, Suh DJ, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS.
    Hepatology; 2009 Oct 21; 50(4):1064-71. PubMed ID: 19637288
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B.
    Lee KS, Kweon YO, Um SH, Kim BH, Lim YS, Paik SW, Heo J, Lee HJ, Kim DJ, Kim TH, Lee YS, Byun KS, Kim D, Lee MS, Yu K, Suh DJ.
    Clin Mol Hepatol; 2017 Dec 21; 23(4):331-339. PubMed ID: 28946736
    [Abstract] [Full Text] [Related]

  • 18. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
    Gish RG, Chang TT, Lai CL, de Man RA, Gadano A, Llamoso C, Tang H.
    Antivir Ther; 2013 Dec 21; 18(5):691-8. PubMed ID: 23510982
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
    Suzuki F, Toyoda J, Katano Y, Sata M, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Kumada H.
    J Gastroenterol Hepatol; 2008 Sep 21; 23(9):1320-6. PubMed ID: 18554238
    [Abstract] [Full Text] [Related]

  • 20. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Chang TT, Chao YC, Gorbakov VV, Han KH, Gish RG, de Man R, Cheinquer H, Bessone F, Brett-Smith H, Tamez R.
    J Viral Hepat; 2009 Nov 21; 16(11):784-9. PubMed ID: 19457141
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.